1. Home
  2. XOMAP vs OKE Comparison

XOMAP vs OKE Comparison

Compare XOMAP & OKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XOMAP
  • OKE
  • Stock Information
  • Founded
  • XOMAP N/A
  • OKE 1906
  • Country
  • XOMAP United States
  • OKE United States
  • Employees
  • XOMAP 13
  • OKE N/A
  • Industry
  • XOMAP Biotechnology: Pharmaceutical Preparations
  • OKE Oil & Gas Production
  • Sector
  • XOMAP Health Care
  • OKE Utilities
  • Exchange
  • XOMAP Nasdaq
  • OKE Nasdaq
  • Market Cap
  • XOMAP N/A
  • OKE N/A
  • IPO Year
  • XOMAP N/A
  • OKE N/A
  • Fundamental
  • Price
  • XOMAP $25.42
  • OKE $83.47
  • Analyst Decision
  • XOMAP
  • OKE Buy
  • Analyst Count
  • XOMAP 0
  • OKE 15
  • Target Price
  • XOMAP N/A
  • OKE $83.85
  • AVG Volume (30 Days)
  • XOMAP N/A
  • OKE 2.3M
  • Earning Date
  • XOMAP N/A
  • OKE 08-05-2024
  • Dividend Yield
  • XOMAP N/A
  • OKE 4.74%
  • EPS Growth
  • XOMAP N/A
  • OKE N/A
  • EPS
  • XOMAP N/A
  • OKE 4.24
  • Revenue
  • XOMAP N/A
  • OKE $17,937,000,000.00
  • Revenue This Year
  • XOMAP N/A
  • OKE $30.63
  • Revenue Next Year
  • XOMAP N/A
  • OKE $6.23
  • P/E Ratio
  • XOMAP N/A
  • OKE $19.73
  • Revenue Growth
  • XOMAP N/A
  • OKE N/A
  • 52 Week Low
  • XOMAP N/A
  • OKE $60.58
  • 52 Week High
  • XOMAP N/A
  • OKE $86.20
  • Technical
  • Relative Strength Index (RSI)
  • XOMAP 47.85
  • OKE 57.11
  • Support Level
  • XOMAP $25.32
  • OKE $82.58
  • Resistance Level
  • XOMAP $25.90
  • OKE $86.20
  • Average True Range (ATR)
  • XOMAP 0.37
  • OKE 1.16
  • MACD
  • XOMAP -0.06
  • OKE 0.11
  • Stochastic Oscillator
  • XOMAP 21.50
  • OKE 47.90

About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock

XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

Share on Social Networks: